Why the study?
The choice of drug for dual antiplatelet therapy in various clinical situations remains controversial.
Do new generation P2Y12 inhibitors (prasugrel and ticagrelor) improve clinical outcomes compared to clopidogrel, and how do they compare to each other, in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Population
Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)
Comparison
New generation P2Y12 platelet receptor inhibitors vs Clopidogrel
Design
Review
Authors
Loading...
May inform DAPT selection by pharmacodynamic profile in ACS; leaves open outcome confirmation in broader populations.
Do new generation P2Y12 inhibitors (prasugrel and ticagrelor) improve clinical outcomes compared to clopidogrel, and how do they compare to each other, in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
This review reinforces current guidelines preferring newer P2Y12 inhibitors (prasugrel and ticagrelor) over clopidogrel for ACS patients undergoing PCI, highlighting a possible preference for prasugrel in specific invasive scenarios.
Uskach et al. (2020) studied this question.